We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fluorescence-Based Photodynamic Product Detects Premalignant/Malignant Colorectal Cancer Lesions

By Labmedica staff writers
Posted on 28 May 2008
A new fluorescence-based photodynamic diagnostic (PDD) product has produced excellent results in a clinical trial evaluating its potential for detecting premalignant/malignant lesions in patients with suspected colorectal cancer.

A dose-finding phase I/II study of the new product, Lumacan, was performed at two hospitals in Germany using fluorescence diagnosis in 38 patients with suspected colorectal cancer. More...
Patients received local instillation of Lumacan in the colon before proceeding with standard colonoscopy using both white and blue (fluorescence) light. The light-sensitive active ingredient in Lumacan, hexalevulinate (HAL), is rapidly accumulated in metabolically active cancerous and precancerous cells, and it fluoresces red when illuminated with blue light.

The results of the study found that of the 91 lesions identified in 25 patients with suspected colorectal cancer using the gold standard approach of tissue histology, 90 lesions were detected using PDD examination with Lumacan, while only 55 lesions were detected using white-light endoscopy. The approach using Lumacan therefore identified 36 more polyps than with the standard clinical procedure of white-light endoscopic imaging, an improvement of approximately 65%. No systemic or local side effects related to the use of Lumacan were reported.

The principle investigator of the trial, Dr. Brigitte Mayinger from the Hospital Munich-Pasing, (Munich, Germany) said, "In this trial, Lumacan conclusively demonstrated its ability to induce specific and selective fluorescence in colorectal lesions thereby significantly increasing the lesion detection rate in patients with colorectal adenoma and early carcinoma compared with standard methods. This new photodynamic diagnosis technique can also detect the flat, nonvisible lesions and hidden polyps that are difficult to observe and which if missed can lead to recurrent or progressive disease.”

Lumacan (hexaminolevulinate) is being developed by Photocure (Oslo, Norway) to improve standard colonoscopy in patients with suspected colorectal cancer. This new product is based on the Hexvix product, which is already approved in Europe for the improved diagnosis of bladder and cancer lesions.

The final study results were presented at Digestive Disease Week (DDW) in San Diego (CA, USA) on May 21, 2008, by Dr. Mayinger.


Related Links:
Photocure

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.